Search
Zilovertamab vedotin
go.drugbank.com/drugs/DB18457Investigationalmc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin. … Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (
Pilavapadin
go.drugbank.com/drugs/DB21552InvestigationalPilavapadin is under investigation in clinical trial NCT06203002 (A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)).
Sulprostone
go.drugbank.com/drugs/DB12708InvestigationalSulprostone has been used in trials studying Abortion, Induced.
Categories: Prostaglandins EHu-PHEC Liver
go.drugbank.com/drugs/DB18347ExperimentalHu-PHEC Liver is an adult hemogenic endothelial cells.
N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium
go.drugbank.com/drugs/DB03945InvestigationalCalcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Synonyms: Ethanaminium, N,N,N-trimethyl-2-(phosphonooxy)-, N,N,N-Trimethyl-2-(phosphonooxy)ethanaminiumCathinone
go.drugbank.com/drugs/DB01560ExperimentalIllicitCathinone was added to the Controlled Substances Act's Schedule I in 1993 in compliance with international laws. … Cathinone is a monoamine alkaloid found in the shrub Catha edulis (Khat).
NKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalChimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties.
Galicaftor
go.drugbank.com/drugs/DB14894Investigationalin Patients With Cystic Fibrosis.). … Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737
Edodekin alfa
go.drugbank.com/drugs/DB15631InvestigationalEdodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic